Back to top
more

Premier (PINC)

(Real Time Quote from BATS)

$25.50 USD

25.50
411,002

-0.92 (-3.48%)

Updated Sep 19, 2025 11:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 245)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Company News for Aug 20, 2025

by Zacks Equity Research

Companies in The News Are: MDT, PINC, PLD, PANW

Zacks Equity Research

Here's What Key Metrics Tell Us About Premier (PINC) Q4 Earnings

by Zacks Equity Research

Although the revenue and EPS for Premier (PINC) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Premier, Inc. (PINC) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Premier (PINC) delivered earnings and revenue surprises of +35.29% and +8.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

IGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of +33.33% and -0.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Countdown to Premier (PINC) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Evaluate the expected performance of Premier (PINC) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Equity Research

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of -28.57% and +15.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sonida Senior Living (SNDA) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Sonida Senior Living (SNDA) delivered earnings and revenue surprises of +79.49% and +0.31%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ascend Wellness Holdings, Inc. (AAWH) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ascend Wellness Holdings, Inc. (AAWH) delivered earnings and revenue surprises of -71.43% and -0.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ardent Health, Inc. (ARDT) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Ardent Health, Inc. (ARDT) delivered earnings and revenue surprises of +73.33% and +7.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should Value Investors Buy Premier (PINC) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Solventum Q1 Earnings Likely to Reflect Higher Costs & Expenses

by Zacks Equity Research

SOLV's Q1 performance is likely to have been hurt by below-par revenue growth in several markets, coupled with currency headwinds. Improved pricing might have offset the sales decline.

Zacks Equity Research

Will Applied Sterilization Growth Help STE Beat Q4 Earnings Estimates?

by Zacks Equity Research

STERIS is expected to have experienced an increase in bioprocessing demand in the fourth quarter.

Zacks Equity Research

Premier (PINC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Premier (PINC) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Premier, Inc. (PINC) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Premier (PINC) delivered earnings and revenue surprises of 41.94% and 9.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MCK Stock Up 24% YTD: Should You Buy, Hold or Sell Before Q4 Earnings?

by Zacks Equity Research

McKesson's fourth-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.

Zacks Equity Research

Will Speciality and GLP-1 Drugs Help COR Beat Q2 Earnings Estimates?

by Zacks Equity Research

COR's fiscal second-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.

Zacks Equity Research

Icon PLC (ICLR) Beats Q1 Earnings Estimates

by Zacks Equity Research

Icon PLC (ICLR) delivered earnings and revenue surprises of 3.57% and 0.58%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Premier, Inc. (PINC) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Premier (PINC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Are Investors Undervaluing Premier (PINC) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Is Premier (PINC) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Should Value Investors Buy Premier (PINC) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

After Plunging -7.95% in 4 Weeks, Here's Why the Trend Might Reverse for Premier (PINC)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Premier (PINC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Are Investors Undervaluing Premier (PINC) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Danaher Rewards Shareholders With 18.5% Dividend Increase

by Zacks Equity Research

DHR's measures to consistently reward shareholders through dividends and share buybacks hold promise.